George Scangos, Biogen

CEO, Biogen
Total 2014 Compensation: $18.63 million

Biogen ($BIIB) has been on a growth streak, fueled by its multiple sclerosis hotshot pill Tecfidera. It recently rolled out two next-gen hemophilia drugs. And it has whetted investors' appetite with early-stage results for an Alzheimer's drug that--if successful, and that's a big if--could zoom to $5 billion in peak sales. The company is so jazzed about its pipeline that it's building a $1 billion plant in Switzerland and figures it will need more manufacturing capacity to keep up.

CEO George Scangos has watched his pay grow, too. Scangos totted up $18.6 million for 2014, up from $15 million in 2013 and $13.45 million the year before that.

Scangos' compensation is heavily weighted toward equity, but he has collected sizable cash incentive pay, too. His base salary was a run-of-the-mill $1.38 million for 2014--on par with that of many other biopharma chiefs--but his incentive pay was on the higher end of things at $4.05 million.

Perhaps that's because Biogen doesn't hand out options. Scangos' equity compensation was all on the stock-award side at $12.12 million. $90,000 in pension benefits and $1 million in other compensation round out the total.

For more:
Special Reports: 15 Highest-Paid Biopharma CEOs of 2013 - George Scangos, Biogen Idec | The 25 most influential people in biopharma today - George Scangos
Biogen to build $1B plant, add 400 jobs in Switzerland
Which Big Biotechs join Gilead in Fortune's fastest-growing pharma ranks?
Biogen's hot MS meds could push Pfizer off its CNS throne
Back-to-'Biogen' shift signals wider industry branding trend
Move over, Big Pharma: Smaller biopharma's execs are bringing home more bacon

George Scangos, Biogen
Read more on

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.